It was suggested that the lack of complete success was due to the failure of the glycerol–saline technique to protect the corneal endothelium. It was therefore decided to investigate directly ...

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

A research team led by Professor Hwang Ho-sik of the Catholic University of Korea's Yeouido St. Mary's Eye Hospital has ...

The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

thus preventing damage to the corneal endothelium. The stiffening effect is concentrated in the anterior 200–300 µm of the cornea due to the high absorption of UV light in this area.

Descemet's stripping automated endothelial keratoplasty (DSAEK) is the gold standard for the surgical treatment of corneal endothelial diseases. Following its introduction over the last decade ...

Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company. It already has ...

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell derived-corneal endothelial cell transplants are injected and take about 20 minutes In Japan ...